FDA Backs Telaprevir for Having High Hepatitis C Cure Rate
Share
Follow Us
The Editors at Hepatitis Central
May 4, 2011
Just a day after doling out similar praise for a comparable drug from Merck, an FDA panel backed the approval of Vertex’s telaprevir, largely due to their computation that this drug’s Hepatitis C cure rate goes far beyond the current therapy’s ability.
Vertex’s hepatitis C drug aces review
Telaprevir cures more people more quickly than current options
April 27, 2011 | By Robert Weisman, Globe Staff
A drug developed by Vertex Pharmaceuticals Inc. cures more patients with the hepatitis C virus in less time than existing therapies, according to a briefing document filed yesterday by Food and Drug Administration staffers who reviewed the company’s application for approval.
Continue reading this entire article:
http://archive.boston.com/business/healthcare/articles/2011/04/27/hepatitis_c_drug_from_vertex_aces_review/
